Non-interventional Study of Ziprasidone in the Treatment of Bipolar and Schizoaffective Disorders.

• Status: Completed
• Trial end date: 2007-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Assessment of ziprasidone safety and efficacy in the treatment of bipolar and schizoaffective disorders.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer; Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
• Treatments: Ziprasidone

Criteria

Inclusion Criteria:

• Manic and mixed episodes of up to moderate severity in patients with Type I and II bipolar disorder and schizoaffective disorder; either first diagnosed or repeated episodes

Exclusion Criteria:

• Hypersensitivity to ziprasidone

• prolonged QTc interval

• coadministration with substances that are prolonging the QTc interval

• recent acute MI, cardiac failure, patients with arrhythmias treated with class IA or III medicaments